Executive Summary
In June 2026, vulnerabilities were identified in the Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT, specifically affecting version 0x0110_v1.1.0. These vulnerabilities, CVE-2026-50034 and CVE-2026-52866, allow attackers within Bluetooth Low Energy (BLE) range to intercept sensitive health data and disrupt device connectivity. The first vulnerability enables unauthorized access to glucose measurement values, while the second allows an attacker to monopolize the device's BLE connection, preventing legitimate use.
These issues highlight the critical need for robust security measures in medical devices, especially those utilizing wireless communication protocols. As healthcare increasingly relies on connected devices, ensuring the confidentiality and availability of patient data is paramount to maintaining trust and compliance with regulatory standards.
Why This Matters Now
The discovery of these vulnerabilities underscores the urgent need for enhanced security in medical IoT devices, as similar threats could compromise patient safety and data integrity.
Attack Path Analysis
An attacker within Bluetooth Low Energy (BLE) range exploited vulnerabilities in the Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT to intercept unencrypted health data and disrupt device connectivity. The attack unfolded as follows: Initially, the attacker intercepted unencrypted BLE communications to access sensitive health information. Subsequently, the attacker monopolized the device's BLE connection slot, preventing legitimate users from connecting. The attacker then maintained control over the device's BLE connection, ensuring continuous disruption. Finally, the attacker exfiltrated the intercepted health data for potential misuse.
Kill Chain Progression
Initial Compromise
Description
An attacker within BLE range intercepted unencrypted communications from the Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT, accessing sensitive health data.
Related CVEs
CVE-2026-50034
CVSS 6.5An attacker within BLE communication range can passively intercept wireless traffic and obtain sensitive health-related information, including glucose measurement values.
Affected Products:
Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT – 0x0110_v1.1.0
Exploit Status:
no public exploitCVE-2026-52866
CVSS 6.5An attacker within BLE communication range can monopolize the device's only available BLE connection slot, preventing legitimate users or applications from establishing a connection.
Affected Products:
Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT – 0x0110_v1.1.0
Exploit Status:
no public exploit
MITRE ATT&CK® Techniques
Application Layer Protocol: Web Protocols
Network Sniffing
Adversary-in-the-Middle: LLMNR/NBT-NS Poisoning and SMB Relay
Network Denial of Service
Valid Accounts
Potential Compliance Exposure
Mapping incident impact across multiple compliance frameworks.
NIST SP 800-53 – Cryptographic Key Establishment and Management
Control ID: SC-12
HIPAA – Transmission Security
Control ID: 164.312(e)(1)
ISO/IEC 27001 – Policy on the Use of Cryptographic Controls
Control ID: A.10.1.1
PCI DSS 4.0 – Use Strong Cryptography and Security Protocols to Protect Sensitive Data During Transmission
Control ID: 4.1
GDPR – Security of Processing
Control ID: Article 32
Sector Implications
Industry-specific impact of the vulnerabilities, including operational, regulatory, and cloud security risks.
Health Care / Life Sciences
Medical device vulnerabilities expose patient glucose data through unencrypted Bluetooth transmission, violating HIPAA compliance and enabling health information theft.
Pharmaceuticals
Apollo Pharmacy's glucose monitoring system vulnerabilities demonstrate IoT security gaps affecting patient care delivery and pharmaceutical device integrity.
Medical Equipment
Bluetooth-enabled glucose monitors lack encryption and authorization controls, creating attack vectors for sensitive health data interception and device monopolization.
Information Technology/IT
IoT medical device security flaws require enhanced encrypted traffic capabilities, zero trust segmentation, and threat detection across healthcare technology infrastructure.
Sources
- Apollo Pharmacy Blood Glucose Monitoring System APG-01 BThttps://www.cisa.gov/news-events/ics-medical-advisories/icsma-26-169-01Verified
Frequently Asked Questions
Cloud Native Security Fabric Mitigations and ControlsCNSF
Aviatrix Zero Trust CNSF is pertinent to this incident as it could likely limit the attacker's ability to intercept unencrypted health data and disrupt device connectivity by enforcing strict segmentation and identity-based policies.
Control: Cloud Native Security Fabric (CNSF)
Mitigation: The attacker's ability to intercept unencrypted health data would likely be constrained, reducing unauthorized access to sensitive information.
Control: Zero Trust Segmentation
Mitigation: The attacker's ability to monopolize the device's BLE connection slot would likely be constrained, reducing the impact on legitimate user access.
Control: East-West Traffic Security
Mitigation: The attacker's ability to maintain control over the device's BLE connection would likely be constrained, reducing continuous disruption.
Control: Multicloud Visibility & Control
Mitigation: The attacker's ability to establish a persistent connection to the device would likely be constrained, reducing ongoing data interception and disruption.
Control: Egress Security & Policy Enforcement
Mitigation: The attacker's ability to exfiltrate intercepted health data would likely be constrained, reducing potential misuse.
The attacker's ability to cause unauthorized access to sensitive health information and denial of service would likely be constrained, reducing the overall impact on legitimate users.
Impact at a Glance
Affected Business Functions
- Patient Health Monitoring
- Medical Data Management
Estimated downtime: N/A
Estimated loss: N/A
Sensitive health-related information, including glucose measurement values.
Recommended Actions
Key Takeaways & Next Steps
- • Implement encrypted traffic controls to secure BLE communications and prevent unauthorized data interception.
- • Enforce strict authorization mechanisms to prevent unauthorized access and monopolization of device connections.
- • Utilize zero trust segmentation to limit device communication to authorized entities only.
- • Deploy threat detection systems to identify and respond to anomalous activities in real-time.
- • Regularly update device firmware to address known vulnerabilities and enhance security features.
